Immunoinformatics based designing of a broad-spectrum multi-epitope vaccine against co-infection of human metapneumovirus, respiratory syncytial virus, and influenza A virus

Why protecting lungs from common winter viruses matters

Every winter, familiar respiratory viruses send millions of people—especially babies, older adults, and those with weak immune systems—to the hospital. Human metapneumovirus, respiratory syncytial virus (RSV), and influenza A often strike at the same time, and sometimes infect the same person together. Such co-infections can make illness more severe, yet today’s vaccines are usually aimed at just one virus at a time. This study explores a new kind of computer-designed vaccine that aims to protect against all three of these major respiratory threats in a single shot.

Three different viruses, one shared problem

RSV, human metapneumovirus, and influenza A all attack the airways, but they do so with different tricks on their surfaces. RSV and metapneumovirus rely on a “fusion” protein to enter cells, while influenza A uses an enzyme called neuraminidase to help new virus particles escape and spread. Current vaccines tend to focus on one virus and on highly changeable regions of these proteins, which can limit how broadly they protect. The authors reasoned that if they could find small stretches of these viral proteins that are both important to the virus and similar across many strains, they might build a single vaccine that works against a wide range of versions of all three viruses.

Building a digital blueprint for a new vaccine

Instead of starting at the lab bench, the team turned first to powerful computer tools—a strategy known as immunoinformatics. They downloaded protein sequences from many strains of the three viruses and used specialized software to scan for tiny fragments, or “epitopes,” that our immune system is likely to recognize. They selected epitopes predicted to alert killer T cells (which destroy infected cells), helper T cells (which organize immune responses), and B cells (which make antibodies). Importantly, they chose only fragments that appeared conserved across many viral strains and that were predicted to be non-toxic and unlikely to trigger allergies. These pieces were then digitally stitched together into a single chain, with short flexible linkers to keep each epitope accessible.

Strengthening the signal to the immune system

To make sure this stitched-together chain would not go unnoticed by the body, the researchers added a built-in “alarm” molecule: a human antimicrobial peptide called beta-defensin-2, which is known to rouse early immune defenses. Using protein-structure modeling, they predicted how the full 442–amino acid construct would fold in three dimensions and checked its stability and solubility. Computer docking experiments suggested that the vaccine could bind tightly to Toll-like receptor 4 (TLR4), a key sensor on immune cells that helps kick-start inflammation and downstream adaptive responses. Simulations of the vaccine–receptor complex over 100 nanoseconds showed a stable partnership with only modest flexing in the vaccine portion—behavior consistent with a well-behaved protein.

Testing immune responses inside a virtual body

Because creating and testing a new vaccine in animals or people is slow and expensive, the team also used a virtual immune system to predict how the construct might behave in the body. In these simulations, three doses given several weeks apart produced strong and rising levels of antibodies as well as a surge in key signaling molecules like interferon-gamma and interleukin-2, which are linked to clearing viral infections and forming long-lasting immune memory. The model predicted robust populations of both helper and killer T cells, along with the formation of memory cells that could respond quickly to later encounters with the viruses. Another analysis suggested that the chosen epitopes would be visible to common immune gene variants in many parts of the world, implying broad population coverage.

From computer design to future real-world protection

Finally, the researchers checked whether the vaccine blueprint could, in principle, be manufactured in a common bacterial system used for protein production. By re-writing the genetic code in a form favored by Escherichia coli, they achieved values that indicate the construct should be efficiently produced in that host, at least on paper. Overall, the study concludes that this multi-epitope vaccine is stable in simulations, likely to be seen by both arms of the immune system, and potentially effective against a broad range of RSV, metapneumovirus, and influenza A strains. While all of these findings are based on computer models and must be confirmed in lab and animal studies, they outline a promising path toward a single, broad-spectrum shot that could help shield vulnerable people from a trio of common and sometimes deadly respiratory viruses.

Citation: Li, L., Chen, Y., Wu, S. et al. Immunoinformatics based designing of a broad-spectrum multi-epitope vaccine against co-infection of human metapneumovirus, respiratory syncytial virus, and influenza A virus. Sci Rep 16, 10244 (2026). https://doi.org/10.1038/s41598-026-40812-z

Keywords: respiratory viruses, multi-epitope vaccine, RSV and influenza, immunoinformatics, broad-spectrum immunity